NANBOLIC-P - Nandrolone Propionate 250mg

Category:- Hormones | Type:- Injection

Each ml contains: Nandrolone Propionate 250 mg Oil Base q.s.

PHARMACOLOGICAL ACTION: Nanbolic-P is an injectable anabolic preparation. After injection, nandrolone propionate is gradually
released from the intramuscular depot and subsequently hydrolysed into nandrolone.

INDICATIONS: Certain cases of disseminated breast cancer in women. Osteoporosis due to androgen deficiency in hypogonadal males.

CONTRA-INDICATIONS: Not intended for use in children.

Known or suspected prostatic carcinoma and mammary carcinoma in the male.

Not intended for use in female patients other than those with disseminated breast cancer. Contraindicated in nephrosis or the nephrotic phase of nephritis, cardiac and renal failure, hypercalcaemia, oedema, jaundice, liver disease with impaired bilirubin excretion, testicular and hepatic carcinoma.

DOSAGE AND DIRECTIONS FOR USE:

Nanbolic-P is intended only for deep intramuscular injection preferably into the gluteal muscle. Dosage should be based on therapeutic response and consideration of the benefit/risk ratio. Duration of therapy will depend on the response of the condition and the appearance of adverse reactions. If possible, therapy should be intermittent.  Nanbolic-P should be regarded as adjunetive therapy and adequate quantities of nutrients should be consumed in order to obtain maximal therapeutic effects.

Anaemia of renal disease:
A dose of 50-100 mg per week Nanbolic-P is recommended for women and 100-250 mg per week for men. Drug therapy should be discontinued if no hematologic improvement is seen within the first six months. When used in the treatment of renal insufficiency, adequate iron intake is required for maximal response.

For children from 2 to 13 years of age, the average dose is 25-50 mg every 3 to 4 weeks.

Warnings: Peliosis hepatitis, a condition in which liver and sometimes splenic tissue is replaced with blood-filled cysts, occurred in patients receiving androgenic anabolic steroids. The condition may not be recognized until life-threatening liver failure or intra-abdominal haemorrhage develops. Lesions completely resolve upon discontinuation. Liver cell tumour, often benign and androgen-dependent but sometimes malignant, have occurred, Drug discontinuation often results in regression or cessation of tumour  rowth. Hepatic tumours associated with androgens or anabolic steroids may be silent until life- threatening, intra-abdominal haemorrhage develops. Blood lipid changes, Including decreased HDL and increased LDL, associated with increased risk of atherosclerosis are seen in some patients treated with androgens and anabolic steroids.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Virilisation which appears in sensitive women as hoarseness, acne, hirsutism, and increased libido; in prepubertal boys as an increased frequency of erections and phallic enlargement, and in girls as an increase of pubic hair and clitoral hypertrophy. Hoarseness may be the first symptom of vocal change which may end in a long-lasting, sometimes irreversible deepening of the voice.

OTHER ADVERSE REACTIONS MAY INCLUDE:
Oligospermia and decreased ejaculatory volume; Suppression of ovarian activity, atrophy of the breasts and endometrial tissue. Amenorrhoea and inhibition of  permatogenesis. Water and salt retention. Premature epiphyseal closure. If signs of virilisation develop, treatment should be discontinued. Increase in nitrogen retention and skeletal weight; Oedema; Increased vascularity of the skin; Increased growth of the bone; Elderly males may become over-stimulated.

PATIENTS WITH THE FOLLOWING CONDITIONS SHOULD BE MONITORED:
Latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions), since anabolic steroids may induce salt and fluid retention; diabetes, since anabolic steroids may improve the glucose tolerance and decrease the need for insulin or other antidiabetic drugs; incomplete statural growth, since anabolic steroids in high dosages may accelerate epiphyseal closure; skeletal metastases, since anabolic steroids may induce hypercalcaemia and hypercalciuria in
these patients.

INTERACTIONS:
Anticoagulants. Anabolic steroids may increase sensitivity to oral anticoagulants. Dosage of the anticoagulant may have to be decreased in order to maintain the prothrombin time at the desired therapeutic level. Patients receiving oral anticoagulant therapy require close monitoring, especially when anabolic steroids are started or stopped Anabolic steroids may decrease levels of thyroxine-binding globulin, resulting In decreased total 14 serum levels and increased resin uptake of T3 and 14.
Free thyroid hormone levels remain unchanged.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT: See "Side-effects and special precautions". Treatment is symptomatic and supportive.

PRESENTATION:
Nanbolic-P 250 mg/ml: 10 x 1 ml clear glass ampoules

STORAGE INSTRUCTIONS:
Nanbolic-P should be stored at controlled room temperatures below 30°C and protected from light. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. If it has expired or is damaged, return it to your pharmacist for disposal. Keep out of reach of children. 

Manufactured by:
COOPER PHARMA LIMITED